QC
CATX icon

Quadrature Capital’s Perspective Therapeutics CATX Stock Holding History

Quadrature Capital’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-24,221
Closed -$83.7K – 1287
2025
Q3 		$83.7K Buy
+24,221
New +$88.3K ﹤0.01% 898
2025
Q2 		– Sell
-15,158
Closed -$32.4K – 1086
2025
Q1 		$32.4K Buy
+15,158
New +$45.5K ﹤0.01% 1009

Other funds holding CATX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
NWMG
Nicholson Wealth Management Group Charlestown, South Carolina $172M AUM 10.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Quadrature Capital's CATX Position: Q4 2025 in Review

Quadrature Capital sold out of Perspective Therapeutics (CATX) in Q4 2025, closing a stake of 24,221 shares — an estimated $83.7K sold.

Quadrature Capital first reported a position in CATX in Q1 2025 and held it in 2 quarters. The position peaked at $83.7K in Q3 2025. 117 funds tracked by Wall St. Rank hold CATX as of Q4 2025.

  • Quadrature Capital reported no remaining Perspective Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Quadrature Capital sold 24,221 Perspective Therapeutics shares in Q4 2025, an estimated $83.7K.
  • Quadrature Capital first reported a position in Perspective Therapeutics in Q1 2025 and held it in 2 quarters.
  • Quadrature Capital's Perspective Therapeutics position peaked at $83.7K in Q3 2025.
  • 117 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q4 2025.

Based on Quadrature Capital's 13F filing for Q4 2025, filed 17 Feb 2026.